Advances in macrophage-targeting nanoparticles for the diagnosis and treatment of inflammatory bowel disease.
10.3724/zdxbyxb-2023-0289
- Author:
Sha LIU
1
;
Yi XIA
2
;
Feng JI
3
Author Information
1. Department of Anesthesiology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. liusha1025@zju.edu.cn.
2. Department of Gastroenterology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
3. Department of Gastroenterology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. jifeng@zju.edu.cn.
- Publication Type:Journal Article
- Keywords:
Inflammatory bowel disease;
Macrophage;
Molecular targeted therapy;
Nanoparticles;
Review;
Targeted imaging
- MeSH:
Humans;
Inflammatory Bowel Diseases/therapy*;
Intestines;
Macrophages/metabolism*;
Intestinal Mucosa/pathology*;
Nanoparticles
- From:
Journal of Zhejiang University. Medical sciences
2023;52(6):785-794
- CountryChina
- Language:English
-
Abstract:
The pathogenesis of inflammatory bowel disease (IBD) is not fully elucidated. However, it has been considered that inflammatory macrophages may be involved in the imbalance of the intestinal mucosal immunity to regulate several signaling pathways, leading to IBD progression. The ratio of M1 to M2 subtypes of activated macrophages tends to increase in the inflamed intestinal section. There are challenges in the diagnosis and treatment of IBD, such as unsatisfactory specificity of imaging findings, low drug accumulation in the intestinal lesions, unstable therapeutic efficacy, and drug-related systemic toxicity. Recently developed nanoparticles may provide a new approach for the diagnosis and treatment of IBD. Nanoparticles targeted to macrophages can be used as contrast agents to improve the imaging quality or used as a drug delivery vector to increase the therapeutic efficiency of IBD. This article reviews the research progress on macrophage-targeting nanoparticles for the diagnosis and treatment of IBD to provide a reference for further research and clinical application.
